Consistent with reports showing that GM-CSF upregulates CCR7 chemokine receptor expression on DCs,30 we demonstrated that tumor CD103+ DCs from mice administered rlipoE7m-MoGM exhibited a high expression level of CCR7, suggesting that this treatment might provide critical tumor-specific T cell priming by transporting tumor antigens to the TdLNs.31 However, unlike the events seen with Flt3 ligand promoting the differentiation and expansion of CD103+ cDC1s,32 the number of CD103+ DCs was not quantitatively changed in the tumors following rlipoE7m-MoGM vaccination. This evidence concerns the gene CCR7 and neoplasm.